Condition: Atopic Dermatitis · Sponsor: Castle Biosciences Incorporated
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.
This description comes directly from the study's public registry record.
Clare Johnson E VP Clinical Research · 602-499-0301 · cjohnson@castlebiosciences.com
Always discuss trial participation with your own doctor first.
| U.S. Dermatology Partners | Phoenix, Arizona, United States | Recruiting |
| Las Vegas Dermatology | Las Vegas, Nevada, United States | Recruiting |
| StracSkin, PLLC | Portsmouth, New Hampshire, United States | Recruiting |
| Harrison Institute for Clinical Research | Missouri City, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07645820